person

Kimberly E Vanover, PhD

as of 2026-07-01
at a glance
Roles: Study Director, Author
KOL signal score 20
9 publications · 5 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.

Profile

Affiliation
Intra-Cellular Therapies
Roles
Study Director, Author
KOL signal
20
Publications
9 (5 high-value)
Trial investigator
no

Publishes on

1 drugs

Trials led

1

Publications & congress

9
Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial.
International clinical psychopharmacology · 2026 · high-value
Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial.
Bipolar disorders · 2023 · high-value
Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.
The American journal of psychiatry · 2021 · high-value
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.
JAMA psychiatry · 2020 · high-value
Dopamine D
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019 · high-value
Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia.
Schizophrenia research · 2021
A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia.
Advances in pharmacology (San Diego, Calif.) · 2021
Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials.
International clinical psychopharmacology · 2021
Effect Size and Blinding in Lumateperone Trial-Reply.
JAMA psychiatry · 2020

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here